# NCT06841055 (NCT06841055)

> Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06841055
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: BioNTech SE
- Conditions: Non-small Cell Lung Cancer
- Interventions: Pumitamig; Docetaxel
- Enrollment: 60
- Primary outcome: Part 1 - Occurrence of dose limiting toxicities (DLTs)
- Primary outcome: Part 1 and Part 2 - Occurrence of pumitamig treatment emergent adverse events, treatment-related adverse events, treatment emergent serious adverse events, treatment-related serious adverse events, and adverse events of special interest
- Primary outcome: Part 1 and Part 2 - Occurrence of dose interruption, dose reduction, and/or participant discontinuation due to adverse events
- Primary outcome: Part 1 and Part 2 - Objective response rate

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 25
- Bluesky threads: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct06841055

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06841055", "email": "<work email>"}; the inbox owner confirms by the emailed link.